Sophie’s Choice for Oncologists: Who Gets New Life-Saving Drug – Newsmax
Newsmax |
Sophie’s Choice for Oncologists: Who Gets New Life-Saving Drug
Newsmax Unlike pills or chemotherapy, the therapy known as CAR–T can’t be stockpiled. Because it’s a bespoke treatment that involves re-engineering a patient’s cells in a specialized lab, the logistics of getting CAR–T to the thousands of Americans who will be … Novartis AG (ADR) (NYSE:NVS) To Face FDA Panel For Cancer Treatment, Kite Pharma Inc (NASDAQ:KITE) Could …Market Exclusive |
Newsmax |
Sophie’s Choice for Oncologists: Who Gets New Life-Saving Drug
Newsmax Unlike pills or chemotherapy, the therapy known as CAR–T can’t be stockpiled. Because it’s a bespoke treatment that involves re-engineering a patient’s cells in a specialized lab, the logistics of getting CAR–T to the thousands of Americans who will be … Novartis AG (ADR) (NYSE:NVS) To Face FDA Panel For Cancer Treatment, Kite Pharma Inc (NASDAQ:KITE) Could …Market Exclusive |
Newsmax |
Sophie’s Choice for Oncologists: Who Gets New Life-Saving Drug
Newsmax Unlike pills or chemotherapy, the therapy known as CAR–T can’t be stockpiled. Because it’s a bespoke treatment that involves re-engineering a patient’s cells in a specialized lab, the logistics of getting CAR–T to the thousands of Americans who will be … |
The Advertiser |
Brothers Michael and Alex Wood share a stem cell bond at the Stadium Stomp
The Advertiser Michael has fought cancer three times since being diagnosed in Year 8, the latest bout helped by a stem cell transplant from brother Alex. Michael, 22, of Redwood Park, was diagnosed with the blood cancer Hodgkin’s lymphoma at age 13. After six rounds … Private clinics’ peddling of unproven stem cell treatments is unsafe and unethicalThe Conversation AU Diabetes alert: Stem Cell Educator therapy is safe and effective for treatmentHindustan Times Standardized Stem CellsHuffPost Guardian (blog) –Business Wire (press release) –eHealth Magazine | Elets all 18 news articles » |
|
J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it
Endpoints News A little more than three years ago, J&J stepped up with a $12.5 million upfront to rent a front row seat on Capricor Therapeutics’ $CAPR Phase II stem cell study, looking to see if their off-the-shelf approach could mend a damaged heart. At the time … |